Free Trial

Eliem Therapeutics (ELYM) Competitors

Eliem Therapeutics logo
$1.48 0.00 (0.00%)
As of 07/24/2025

ELYM vs. VYGR, DMAC, BDTX, GALT, IPHA, SLS, ACRS, IMAB, TIL, and PBYI

Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Voyager Therapeutics (VYGR), DiaMedica Therapeutics (DMAC), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Innate Pharma (IPHA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), I-Mab (IMAB), Instil Bio (TIL), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

Eliem Therapeutics vs. Its Competitors

Eliem Therapeutics (NASDAQ:ELYM) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Voyager Therapeutics had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for Eliem Therapeutics. Voyager Therapeutics' average media sentiment score of 0.02 beat Eliem Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Eliem Therapeutics Neutral
Voyager Therapeutics Neutral

Eliem Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -126.49%. Voyager Therapeutics' return on equity of -27.36% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Voyager Therapeutics -126.49%-27.36%-21.06%

Eliem Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.79
Voyager Therapeutics$66.96M2.68-$65M-$1.46-2.22

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Voyager Therapeutics has a consensus price target of $13.39, indicating a potential upside of 313.27%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Voyager Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Summary

Voyager Therapeutics beats Eliem Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELYM vs. The Competition

MetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$44.03M$778.65M$5.74B$9.51B
Dividend YieldN/A4.84%4.60%3.99%
P/E Ratio-2.791.4028.1120.03
Price / SalesN/A26.88460.63103.88
Price / CashN/A19.5636.5559.01
Price / Book0.386.798.655.90
Net Income-$35.12M-$4.32M$3.25B$258.66M
7 Day Performance1.37%1.40%4.20%2.23%
1 Month Performance14.73%4.36%10.83%12.77%
1 Year Performance-83.37%8.18%34.67%19.36%

Eliem Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELYM
Eliem Therapeutics
N/A$1.48
flat
N/A-82.9%$44.03MN/A-2.799Gap Down
VYGR
Voyager Therapeutics
3.8656 of 5 stars
$3.17
-2.2%
$13.39
+322.4%
-62.8%$179.29M$66.96M-2.17100
DMAC
DiaMedica Therapeutics
1.173 of 5 stars
$4.54
+8.6%
$10.75
+136.8%
+33.7%$179.25MN/A-7.0920High Trading Volume
BDTX
Black Diamond Therapeutics
2.9635 of 5 stars
$3.15
+0.6%
$12.80
+306.3%
-48.7%$177.98MN/A52.5090Positive News
GALT
Galectin Therapeutics
2.4432 of 5 stars
$2.74
-2.1%
$6.00
+119.0%
+14.0%$177.22MN/A-3.819
IPHA
Innate Pharma
2.6261 of 5 stars
$1.87
-2.9%
$11.00
+489.8%
-10.0%$176.99M$21.77M0.00220Positive News
Gap Up
SLS
SELLAS Life Sciences Group
2.3223 of 5 stars
$1.85
+4.5%
$7.00
+278.4%
+53.8%$176.61M$1M-4.8710Positive News
ACRS
Aclaris Therapeutics
2.3799 of 5 stars
$1.64
+1.9%
$8.71
+431.4%
+21.7%$174.33M$17.78M-1.18100Positive News
Gap Up
IMAB
I-Mab
2.869 of 5 stars
$2.12
+1.0%
$6.00
+183.0%
+50.4%$171.49M$3.89M0.00380
TIL
Instil Bio
3.1676 of 5 stars
$27.62
+5.8%
$119.00
+330.8%
+151.7%$171.19MN/A-2.31410Positive News
PBYI
Puma Biotechnology
4.233 of 5 stars
$3.41
+0.3%
$7.00
+105.3%
-8.8%$168.74M$230.50M4.43200Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:ELYM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners